ConductScience.org, home

Trial · NCT03093246

Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis

NCT03093246, Phase 2, Phase 3, Completed, Universidade Estadual Paulista Júlio de Mesquita Filho; results first posted 2021-07-29

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis. Trials, record NCT03093246. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03093246

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis
NCT number
NCT03093246
Status
Completed
Phases
Phase 2, Phase 3
Enrollment
38 participants, actual
Lead sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
Conditions
Aggressive Periodontitis
Interventions
Omega-3 polyunsaturated fatty acids, Aspirin, Placebo, Full-mouth ultrasonic debridement
First posted
2017-03-28
Last updated
2021-12-28
Results first posted
2021-07-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in Probing DepthBaseline, 3 and 6 monthsEvaluate the difference between baseline and 6 months PD measures.
SecondaryChange in Clinical Attachment LevelBaseline, 3 and 6 monthsEvaluate the difference between baseline and 6 months CAL measures.
SecondaryChange in Bleeding on ProbeBaseline, 3 and 6 monthsEvaluate the difference between baseline and 6 months BoP measures

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYChange in Probing DepthBaseline, 3 and 6 monthsmilimetersMEAN
SECONDARYChange in Clinical Attachment LevelBaseline, 3 and 6 monthsmilimetersMEAN
SECONDARYChange in Bleeding on ProbeBaseline, 3 and 6 monthspercentage of sites with BoPMEAN

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change in Probing DepthControl GroupBaseline3.88Standard Deviation 0.15milimeters
Change in Probing DepthTest GroupBaseline3.74Standard Deviation 0.15milimeters
Change in Probing DepthControl Group3 months3.38Standard Deviation 0.14milimeters
Change in Probing DepthTest Group3 months3.26Standard Deviation 0.13milimeters
Change in Probing DepthControl Group6 months3.37Standard Deviation 0.14milimeters
Change in Probing DepthTest Group6 months3.25Standard Deviation 0.13milimeters
Change in Clinical Attachment LevelControl GroupBaseline3.94Standard Deviation 0.17milimeters
Change in Clinical Attachment LevelTest GroupBaseline4.01Standard Deviation 0.21milimeters
Change in Clinical Attachment LevelControl Group3 months3.58Standard Deviation 0.17milimeters
Change in Clinical Attachment LevelTest Group3 months3.65Standard Deviation 0.21milimeters

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDControl Group19
Overall StudySTARTEDTest Group19
Overall StudyCOMPLETEDControl Group19
Overall StudyCOMPLETEDTest Group19
Overall StudyNOT COMPLETEDControl Group0
Overall StudyNOT COMPLETEDTest Group0

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityControl Group019
Total, all-cause mortalityTest Group019
Total, other adverse eventsControl Group019
Total, other adverse eventsTest Group019
Total, serious adverse eventsControl Group019
Total, serious adverse eventsTest Group019

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
20572767BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource
Test Group vs Control Group: deaths from any causeTrial comparisons
Test Group vs Control Group: serious adverse eventsTrial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03093246

GET https://conductscience.org/api/trials/v1/NCT03093246/registered